Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 2Neoplasm Metastasis 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1

Interventions

Pemetrexed 22Carboplatin 22Cisplatin 19Paclitaxel 9Gemcitabine 9pembrolizumab 8osimertinib 7Nivolumab 6Crizotinib 6durvalumab 5atezolizumab 5amivantamab 4Ipilimumab 4Docetaxel 4Afatinib 4tremelimumab 3lazertinib 3Vinorelbine 3Gefitinib 3Etoposide 3Albumin-Bound Paclitaxel 3trametinib 2selpercatinib 2lorlatinib 2larotrectinib 2dabrafenib 2cemiplimab 2binimetinib 2alectinib 2PM 01183 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Gefitinib × Thoracic × Clear all
NCT02296125 2026-04-21

FLAURA

AstraZeneca

Phase 3 Completed
674 enrolled 21 charts 1 FDA
Thoracic

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT02411448 2026-01-16

RELAY

Eli Lilly and Company

Phase 3 Active not recruiting
545 enrolled 24 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01774721 2023-11-14

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Pfizer

Phase 3 Completed
452 enrolled 35 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡